Kodiak Sciences Inc. — Investor Relations & Filings

Kodiak Sciences Inc. is a clinical-stage biopharmaceutical company focused on researching, developing, and commercializing therapeutics for chronic, high-prevalence retinal diseases. The company's mission is to address the leading causes of blindness, such as wet age-related macular degeneration (AMD), diabetic retinopathy, and retinal vein occlusion. Its core technology is the proprietary Antibody Biopolymer Conjugate Drug (ABCD) Platform, which is designed to create long-acting biologics with enhanced durability, potentially reducing treatment frequency for patients. Kodiak's late-stage clinical pipeline includes its lead candidate, tarcocimab tedromer, an anti-VEGF therapy, as well as other candidates targeting retinal vascular diseases and macular edema.